Pharmaceuticals

Furui Co.,Ltd.

Furui Co., Ltd. released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 360.14 M, actual EPS CNY 0.12

Furui Co., Ltd. FY2026 Q1 Earnings Release on April 28 After-Market (BJT)

Furui Co., Ltd. released FY2025 annual earnings on March 24 After-Market (BJT), actual revenue CNY 1.595 B (forecast CNY 1.601 B), actual EPS CNY 0.58 (forecast CNY 0.71)

Furui Co., Ltd released FY2025 Q4 earnings on March 24 After-Market (BJT), actual revenue CNY 494.34 M, actual EPS CNY 0.1543

Furui Co., Ltd to release FY2025 earnings on March 25 After-Market (BJT), forecast revenue CNY 1.601 B, EPS CNY 0.71

Furui Co., Ltd released FY2025 Q3 earnings on October 28 During-Market (BJT), actual revenue CNY 387.63 M, actual EPS CNY 0.2283

Furui Co., Ltd. released FY2025 9 Months Earnings on October 28 During-Market (BJT), actual revenue CNY 1.101 B, actual EPS CNY 0.4278

Furui Co., Ltd to Release FY2025 Q3 Earnings on October 29 During-Market BJT

Furui Co., Ltd released FY2025 Q2 earnings on August 21 After-Market BJT, actual revenue CNY 383.01 M, actual EPS CNY 0.0894

Furui Co., Ltd released FY2025 Semi-Annual earnings on August 21 After-Market (BJT), actual revenue CNY 713.42 M, actual EPS CNY 0.1972

Furui Co., Ltd to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

FibroScan Devices Collaborate with MASH Enterprises

Furui Share Reponds to Shareholder Numbers and Performance Impact

Fibroscan Demand Surges with NASH New Drug Launch

Furui Shares Subsidiary Wins Tender from UK NHS Supply Chain

FuRui Shares Plans to Acquire Equity of Chengdu FuRuihui Hospital Management Co., Ltd.

Fure Share Announces a 32.97% Decline in Net Profit for Q1 2025

Furui Co., Ltd. released FY2024 earnings on April 21 After-Market (BJT), actual revenue CNY 1.349 B (forecast CNY 1.562 B), actual EPS CNY 0.43 (forecast CNY 0.7466)

Furui Co., Ltd. released FY2024 Q4 earnings on April 21 After-Market BJT, actual revenue CNY 369.15 M, actual EPS CNY 0.0441

Furui Co., Ltd. released FY2025 Q1 earnings on April 21 After-Market BJT, actual revenue CNY 330.4 M, actual EPS CNY 0.11

The global stigmasterol-rich plant sterols market is projected to reach USD 1,281.42 million by 2036, driven by rising cardiovascular health awareness and demand for functional foods. The market is transitioning towards standardized formulations and regulatory support, with significant growth in applications across food, nutraceuticals, and pharmaceuticals. Key growth regions include India, Germany, and China, with a forecast CAGR of 3.8% from 2026 to 2036. The market is bolstered by increasing consumer preference for plant-based wellness solutions and regulatory approvals for health claims.

MorningStar

Stigmasterol-Rich Plant Sterols Market to Reach USD 1,281.42 Million by 2036 as Cardiovascular Health Awareness and Functional Food Demand Expand Globally

688566

688136

002250

300049

688062

Caitong Securities released a research report indicating that phosphoramidite monomers play a key role in the development of small nucleic acid drugs, and demand is expected to grow significantly in the future. According to predictions from sphericalinsights, global sales of nucleotides will reach USD 730 million in 2023, with China being the largest production market, primarily focused on exports. Small nucleic acid drugs are considered potential treatment options for various diseases due to their unique molecular structure and therapeutic mechanisms, and companies within the supply chains of multinational pharmaceutical companies are expected to benefit from this

Zhitong

Jibeier Pharmaceutical

SDKX

LIANHE TECHNOLOGY

Mabwell

Caitong Securities: The demand for phosphonamide monomers will flourish, and multinational pharmaceutical companies' supply chain enterprises are expected to benefit

Furui Co., Ltd. announced that the revenue for the third quarter was 388 million yuan, a year-on-year increase of 14.94%; the net profit was 59.9522 million yuan, a year-on-year increase of 125.06%. The revenue for the first three quarters was 1.101 billion yuan, a year-on-year increase of 12.37%; the net profit was 112 million yuan, a year-on-year increase of 9.69%

Furui Co., Ltd: Net profit in the third quarter was 59.9522 million yuan, a year-on-year increase of 125.06%

According to the Zhitong Finance APP, Furui Co., Ltd. released its semi-annual report for 2025, reporting an operating income of 713 million yuan, a year-on-year increase of 11.02%. The net profit attributable to shareholders of the listed company was 51.934 million yuan, a year-on-year decrease of 31.09%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 53.323 million yuan, a year-on-year decrease of 28.39%. The basic earnings per share were 0.1972 yuan

Furui Co., Ltd. released its performance for the first half of the year, with a net profit attributable to the parent company of 51.934 million yuan, a decrease of 31.09%

688336

688098

300199

688621

688091

In the morning session, the innovative drug concept became active again, with Shen Lian Biomedical hitting a two-day limit-up, Furui Co., Ltd. reaching a 20% limit-up, and HYBIO, Sun-Novo, SHANGHAI YIZHONG, and Sunshine Guojian Pharmaceutical rising over 5%. According to news, the "China Innovative Drug and Medical Device Multi-Payment White Paper" shows that the estimated scale of China's innovative drug and medical device market in 2024 is about 162 billion yuan. The white paper predicts that by 2035, the market size of innovative drugs and medical devices in China will exceed 1 trillion yuan

Sunshine Guojian Pharmaceutical

Shen Lian Biomedical

HYBIO

Sun-Novo

SHANGHAI YIZHONG

The concept of innovative drugs is active again, Shen Lian Biomedical has achieved a two-day limit up

According to the Zhitong Finance APP, Furui Co., Ltd. released its 2024 annual report, showing an operating income of 1.349 billion yuan, a year-on-year increase of 16.93%. The net profit attributable to shareholders of the listed company was 113 million yuan, a year-on-year increase of 11.54%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 118 million yuan, a year-on-year increase of 19.33%. The basic earnings per share were 0.4285 yuan

Furui Co., Ltd. released its 2024 annual performance, with a net profit attributable to the parent company of 113 million yuan, an increase of 11.54%

Furui Co., Ltd. announced that its revenue for the first quarter of 2025 was 330 million yuan, a year-on-year increase of 2.35%; net profit was 28.6367 million yuan, a year-on-year decrease of 32.97%

Furui Co., Ltd: Net profit in the first quarter of 2025 was 28.6367 million yuan, a year-on-year decrease of 32.97%

The global human liver model market is projected to grow from USD 1.34 billion in 2024 at a CAGR of 14.04% from 2025 to 2030, driven by rising liver disease prevalence, advancements in 3D bioprinting, and increased demand for liver cancer therapeutics. The report highlights the urgent need for accurate human liver models due to chronic liver conditions like NAFLD affecting 25% of the global population. Significant advancements in organ printing technologies are transforming healthcare, addressing organ shortages, and improving patient care.

GlobeNewswire

Global Human Liver Model Market 2025-2030: Growth Driven by 3D Bioprinting & Liver Disease Research

According to the Zhitong Finance APP, Furui Co., Ltd. has released its performance forecast for 2024. The company expects a net profit attributable to shareholders of the listed company to be between 112 million yuan and 142 million yuan, a year-on-year increase of 10% to 40%; the net profit after deducting non-recurring gains and losses is expected to be between 108 million yuan and 138 million yuan, a year-on-year increase of 9% to 40%

Furui Co., Ltd. issued a profit forecast, expecting a net profit of 112 million to 142 million yuan for the year 2024, a year-on-year increase of 10% to 40%

Furui Co.,Ltd.(300049.SZ)